Regulatory Approval

Regulatory Approval

Eco Animal Health Group Plc

27 January 2014

ECO Animal health Group plc

(AIM: EAH)

ECO RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR AIVLOSIN^® FOR TURKEYS

ECO is pleased to announce that it has received a marketing authorization from the European Medicines Agency (EMA) for the use of Aivlosin^® 625 mg/g water soluble granules in turkeys. This authorization allows for the medication of drinking water with Aivlosin^® for the treatment of respiratory disease associated with Ornithobacterium rhinotracheale (ORT) in turkeys.

Aivlosin^® is the first antibiotic to be granted approval in Europe for this specific indication, an economically important respiratory disease. Europe has a 30 per cent share of global turkey meat production.

Aivlosin^®, ECO’s patented macrolide antibiotic, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

Peter Lawrence, Chairman, commented “This European market authorization is a further encouraging step in the ongoing development of Aivlosin^® as a multi-species, versatile brand that treats a multitude of different diseases. It underlines ECO’s commitment to be a major force in the global market for animal health products.”

Contacts:

ECO Animal Health Group plc	Â
Peter Lawrence		020 8336 6190
Spiro Financial		020 8336 6196
Cenkos Securities plc (Nominated Adviser)
Stephen Keys		020 7397 8926

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for the global markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

Eco Animal Health Group Plc

Source: Eco Animal Health Group Plc